Amylyx Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AMLX) $14.16 +0.58 (+4.27%) (As of 11/30/2023 ET) Add Compare Share Share Today's Range$13.44▼$14.3750-Day Range$12.07▼$18.8152-Week Range$11.82▼$41.93Volume1.38 million shsAverage Volume1.16 million shsMarket Capitalization$956.05 millionP/E RatioN/ADividend YieldN/APrice Target$46.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Amylyx Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside224.9% Upside$46.00 Price TargetShort InterestHealthy14.19% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.64Based on 7 Articles This WeekInsider TradingN/AProj. Earnings Growth105.88%From $0.85 to $1.75 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.79 out of 5 starsMedical Sector79th out of 949 stocksPharmaceutical Preparations Industry25th out of 437 stocks 3.5 Analyst's Opinion Consensus RatingAmylyx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $46.00, Amylyx Pharmaceuticals has a forecasted upside of 224.9% from its current price of $14.16.Amount of Analyst CoverageAmylyx Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted14.19% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently decreased by 10.84%, indicating that investor sentiment is improving significantly. Previous Next 0.8 Dividend Strength Dividend YieldAmylyx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmylyx Pharmaceuticals does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Amylyx Pharmaceuticals will have a dividend payout ratio of 58.06% next year. This indicates that Amylyx Pharmaceuticals will be able to sustain or increase its dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMLX. Previous Next 2.0 News and Social Media Coverage News SentimentAmylyx Pharmaceuticals has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Amylyx Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 10 people have searched for AMLX on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amylyx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders11.80% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.70% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Amylyx Pharmaceuticals are expected to grow by 105.88% in the coming year, from $0.85 to $1.75 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amylyx Pharmaceuticals is -708.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amylyx Pharmaceuticals is -708.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioAmylyx Pharmaceuticals has a PEG Ratio of 0.23. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAmylyx Pharmaceuticals has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More AMLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMLX Stock News HeadlinesNovember 29, 2023 | finance.yahoo.comAmylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 28, 2023 | finance.yahoo.comAmylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical OfficerDecember 1, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 27, 2023 | finance.yahoo.comRELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MNDNovember 24, 2023 | seekingalpha.comAmylyx Pharmaceuticals: A Compelling Buy In The Biotech SectorNovember 23, 2023 | seekingalpha.comAmylyx Pharmaceuticals: Balancing Growth And Market Challenges (Rating Downgrade)November 21, 2023 | finance.yahoo.comAmylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx ConferenceNovember 14, 2023 | benzinga.comKirby McInerney LLP Announces Investigation of Shareholder Claims Against Amylyx Pharmaceuticals, Inc. (AMLX)December 1, 2023 | Tomorrow Investor (Ad)Why Microsoft Just Placed A Huge Bet On NuclearEven with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.November 12, 2023 | finance.yahoo.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2023 Earnings Call TranscriptNovember 10, 2023 | finance.yahoo.comQ3 2023 Amylyx Pharmaceuticals Inc Earnings CallNovember 10, 2023 | finance.yahoo.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock's 34% Dive Might Signal An Opportunity But It Requires Some ScrutinyNovember 9, 2023 | finance.yahoo.comAmylyx Crashes 32% On A Quarterly Report That Doesn't Bode Well For 2024November 9, 2023 | msn.comAmylyx Crashes 26% As New ALS Drug Faces A Barrage Of TroublesNovember 9, 2023 | finance.yahoo.comAmylyx Crashes 27% As New ALS Drug Faces A Barrage Of TroublesNovember 9, 2023 | markets.businessinsider.comAnticipating the Impact of TUDCA-ALS Study on Amylyx Pharmaceuticals: An Investment PerspectiveNovember 9, 2023 | finance.yahoo.comAmylyx Pharmaceuticals Reports Third Quarter 2023 Financial ResultsNovember 9, 2023 | finance.yahoo.comAmylyx Pharmaceuticals Inc (AMLX) Reports Strong Q3 2023 Earnings with Significant Revenue GrowthNovember 4, 2023 | morningstar.comAmylyx Pharmaceuticals Inc AMLXNovember 4, 2023 | insidermonkey.com5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge FundsNovember 4, 2023 | finance.yahoo.com12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge FundsNovember 2, 2023 | finance.yahoo.comAmylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023October 19, 2023 | finance.yahoo.comAmylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research SymposiumOctober 17, 2023 | markets.businessinsider.comBuy Rating for Amylyx Pharmaceuticals Maintained Despite CHMP’s Negative Opinion on AMX0035: An Analysis by Graig SuvannavejhOctober 13, 2023 | markets.businessinsider.comAmylyx Receives Negative CHMP Opinion On MAA For AMX0035 For Amyotrophic Lateral Sclerosis TreatmentOctober 13, 2023 | reuters.comEU regulator declines to recommend Amylyx' ALS drugOctober 13, 2023 | finance.yahoo.comAmylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination ProcessSee More Headlines Receive AMLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2023Today11/30/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AMLX CUSIPN/A CIK1658551 Webamylyx.com Phone617-682-0917FaxN/AEmployees374Year FoundedN/APrice Target and Rating Average Stock Price Target$46.00 High Stock Price Target$50.00 Low Stock Price Target$40.00 Potential Upside/Downside+224.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E Ratio16.66 P/E Growth0.23Net Income$-198,380,000.00 Net Margins0.62% Pretax Margin1.94% Return on Equity0.49% Return on Assets0.43% Debt Debt-to-Equity RatioN/A Current Ratio9.52 Quick Ratio8.81 Sales & Book Value Annual Sales$294.22 million Price / Sales3.25 Cash FlowN/A Price / Cash FlowN/A Book Value$6.20 per share Price / Book2.28Miscellaneous Outstanding Shares67,518,000Free Float59,551,000Market Cap$956.05 million OptionableNot Optionable Beta-0.68 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Joshua B. Cohen (Age 31)Co-Founder, Co-CEO & Director Comp: $1MMr. Justin B. Klee (Age 32)Co-Founder, Co-CEO & Director Comp: $1MMr. James M. Frates M.B.A. (Age 56)Chief Financial Officer Comp: $695.12kMs. Gina M. Mazzariello (Age 52)Chief Legal Officer & General Counsel Comp: $794.83kMr. Tom HolmesChief Technical Operations OfficerLindsey AllenHead of Investor Relations & CommunicationsMs. Shauna HorvathHead of Global MarketingMs. Debra L. Canner (Age 64)Global Head of Human Resources & CHRO Ms. Margaret M. Olinger M.B.A (Age 58)Global Head of Commercial & Chief Commercial Officer Comp: $567kDr. Patrick D. Yeramian M.D. (Age 64)MBA, Ph.D., Global Head of Clinical R&D and Chief Medical Officer Comp: $497.84kMore ExecutivesKey CompetitorsInnovivaNASDAQ:INVACassava SciencesNASDAQ:SAVAAlpine Immune SciencesNASDAQ:ALPNKeros TherapeuticsNASDAQ:KROSPliant TherapeuticsNASDAQ:PLRXView All CompetitorsInsiders & InstitutionsDeutsche Bank AGSold 167,195 shares on 11/24/2023Ownership: 0.036%Graham Capital Management L.P.Bought 25,689 shares on 11/22/2023Ownership: 0.083%Walleye Capital LLCBought 1,800 shares on 11/21/2023Ownership: 0.000%Tudor Investment Corp Et AlSold 32,256 shares on 11/16/2023Ownership: 0.041%GTS Securities LLCBought 10,700 shares on 11/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions AMLX Stock Analysis - Frequently Asked Questions Should I buy or sell Amylyx Pharmaceuticals stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AMLX shares. View AMLX analyst ratings or view top-rated stocks. What is Amylyx Pharmaceuticals' stock price target for 2024? 5 equities research analysts have issued 12-month price objectives for Amylyx Pharmaceuticals' shares. Their AMLX share price targets range from $40.00 to $50.00. On average, they anticipate the company's stock price to reach $46.00 in the next twelve months. This suggests a possible upside of 224.9% from the stock's current price. View analysts price targets for AMLX or view top-rated stocks among Wall Street analysts. How have AMLX shares performed in 2023? Amylyx Pharmaceuticals' stock was trading at $36.95 on January 1st, 2023. Since then, AMLX stock has decreased by 61.7% and is now trading at $14.16. View the best growth stocks for 2023 here. Are investors shorting Amylyx Pharmaceuticals? Amylyx Pharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totaling 7,070,000 shares, a decrease of 10.8% from the October 31st total of 7,930,000 shares. Based on an average daily trading volume, of 1,490,000 shares, the short-interest ratio is currently 4.7 days. Currently, 14.2% of the company's shares are sold short. View Amylyx Pharmaceuticals' Short Interest. When is Amylyx Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024. View our AMLX earnings forecast. How were Amylyx Pharmaceuticals' earnings last quarter? Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) issued its quarterly earnings data on Monday, March, 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.12. The company earned $21.89 million during the quarter, compared to analysts' expectations of $3.05 million. Amylyx Pharmaceuticals had a net margin of 0.62% and a trailing twelve-month return on equity of 0.49%. Is Amylyx Pharmaceuticals a good dividend stock? Amylyx Pharmaceuticals (NASDAQ:AMLX) pays an annual dividend of $1.02 per share and currently has a dividend yield of 0.00%. What ETFs hold Amylyx Pharmaceuticals' stock? ETFs with the largest weight of Amylyx Pharmaceuticals (NASDAQ:AMLX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH), Virtus LifeSci Biotech Products ETF (BBP), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and ALPS Medical Breakthroughs ETF (SBIO).iShares U.S. Pharmaceuticals ETF (IHE). When did Amylyx Pharmaceuticals IPO? (AMLX) raised $190 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 10,000,000 shares at a price of $18.00-$20.00 per share. Who are Amylyx Pharmaceuticals' major shareholders? Amylyx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (3.73%), Avidity Partners Management LP (2.60%), Adage Capital Partners GP L.L.C. (2.52%), Morgan Stanley (1.41%), Emerald Advisers LLC (1.24%) and Emerald Mutual Fund Advisers Trust (1.01%). Insiders that own company stock include George M Milne Jr, Gina Mazzariello, Global Investors Lp Viking, James M Frates, Justin B Klee, Morningside Venture Investment and Patrick D Yeramian. View institutional ownership trends. How do I buy shares of Amylyx Pharmaceuticals? Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AMLX) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.